Skip to main content

Efficacy analysis and research progress of complementary and alternative medicines in the adjuvant treatment of COVID-19


The coronavirus disease 2019 (COVID-19) pandemic has impacted human lifestyles around the world, causing huge distress in terms of public health systems, emergency response capacity and economic development. The causative agent of COVID-19, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is associated with respiratory involvement, cardiovascular-related diseases, and ultimately causes multiple organ failure and death in severely affected individuals. Thus, effective prevention or early treatment of COVID-19 is critical. An effective vaccine offers a way out of the pandemic for governments, the scientific community and people worldwide, but we still lack effective drug therapies, including treatments for the prevention and treatment of COVID-19. This had led to a high global demand for many complementary and alternative medicines (CAMs). Moreover, many healthcare providers are now requesting information about CAMs that prevent, relieve, or treat the symptoms of COVID-19 and even alleviate vaccine-related side effects. Experts and scholars must therefore become familiar with the use of CAMs in COVID-19, current research directions and effectiveness of CAMs for COVID-19. This narrative review updates the current status and research worldwide on the use of CAMs for COVID-19. The review provides reliable evidence on theoretical viewpoints and therapeutic efficacies of CAM combinations, and evidence in support of the therapeutic strategy of Taiwan Chingguan Erhau (NRICM102) against moderate-to-severe novel coronavirus infectious disease in Taiwan.


The COVID-19 pandemic, which spread rapidly around the world after emerging in Wuhan, China in December 2019, remains a global health problem [1], with more than 750 million cases and 6.8 million deaths related to COVID-19 reported by March 2023, with individuals who have compromised immune systems or chronic diseases and the elderly being at high risk ( Despite World Health Organization (WHO) prevention guidelines intended to slow the spread of the virus, the COVID-19 pandemic continues to greatly affect human physiology and psychology. Inadequate prevention and treatment measures, as well as the rapid spread of COVID-19 infection contribute to the perceived unknown risks to humans, so many protective and preventive behaviors have emerged as attempts to reduce these disease-related risks [2, 3]. In addition to the conventional interventions, such as emergency-authorized vaccines and antiviral drugs that are designed to reduce risk and better manage processes to prevent or treat COVID-19 infections, complementary or alternative treatments such as herbal preparations, dietary therapies and vitamin supplements can be used [4,5,6].

CAMs, including traditional herbal remedies, are being implemented in many countries as an option to prevent or treat COVID-19 infections. During the COVID-19 pandemic, it is very important to enhance personal immunity, reduce the side effects of antiviral or anti-inflammatory drugs, and protect individuals from this disease [3, 7]. CAMs are widely believed to improve the quality of life, attitudes towards self-care, and an individual’s health status, although there is currently only limited evidence to support the usefulness of CAMs in reducing viral load and/or symptoms. Some countries, including Taiwan, China and India have engaged in pilot studies designed to assess the efficacies of traditional medicines against coronavirus infections. Traditional Chinese medicine (TCM) has been used for many centuries to treat infectious diseases according to their clinical features and symptoms [8, 9]. Much study evidence claims that TCM has antiviral properties that can improve recovery rates, shorten disease duration, and reduce mortality. The ease of use of TCM and its low cost have contributed to its increased use [10,11,12].

A bedside-to-bench analysis of clinical outcomes and pharmacology has highlighted the therapeutic efficacy of TCM for improving symptoms of pulmonary infiltrates of COVID-19 [13]. The Department of Traditional Chinese Medicine in Taiwan’s Ministry of Health and Welfare has issued guidelines for the clinical staging of treatment of COVID-19 virus [14]. TCM therapies offer promise for the development of COVID-19 drugs in Taiwan [15].

Small molecule therapies for COVID-19

The genetic diversification of SARS-CoV-2 is worryingly rapid, with multiple variants emerging by late 2020 that exacerbated regional epidemics; all five variants of concern (VOC) identified so far (Alpha, Beta, Gamma, Delta, and Omicron) have mutations that encourage their evasion of host immune responses [16]. The spike glycoprotein appears to be particularly prone to accumulating mutations. A vaccine based on the spike protein has been developed and the vaccination program is being given maximum global support. However, serum studies and evidence suggest that Omicron escapes immunity, regardless of prior infection or vaccination [17].

Direct-acting antiviral drugs against SARS-CoV-2 are classified as either monoclonal antibodies (mAbs) against the spike protein, or small molecules that interfere with viral replication. The SARS-CoV-2 VOC Omicron is insensitive to most currently approved mAbs, which have shown poor clinical efficacy [18]. Currently available direct-acting small-molecule SARS-CoV-2 antivirals target the conserved viral RNA-dependent RNA polymerase (RdRp), the conserved viral major protease (the 3C-like protease [3CLpro]), or the main protease (Mpro). Small-molecule therapeutics remdesivir, molnupiravir and Paxlovid (nirmatrelvir plus ritonavir) have shown significant efficacy in the treatment of COVID-19 and been therefore been granted emergency use authorization or have entered phase III trials in many countries [19]. Moreover, many other anti-SARS-CoV-2 drug candidates have been developed and have now entered clinical evaluation. It is hoped that these new drugs will overcome COVID-19.

Remdesivir, originally used to treat the Ebola virus, inhibits the RdRp of SARS-CoV-2. It is the first antiviral to be approved or authorized for emergency use to treat COVID-19, with evidence showing that remdesivir improves the clinical outcomes of hospitalized patients with moderate-to-severe disease and prevents the progression of COVID-19 in outpatients [20].

The oral biologic molnupiravir also inhibits viral RdRp and was originally used against different RNA viruses such as influenza. In a phase 2a clinical trial, molnupiravir accelerated the clearance of SARS-CoV-2 RNA and eliminated infectious virus in patients with COVID-19 [21]. In the UK, molnupiravir has been authorized for use in patients with mild-to-moderate COVID-19 and at least one risk factor for developing severe disease [22]. The UK-based phase 2 trial (AGILE CST-2) involving vaccinated and unvaccinated patients with early COVID-19 infection showed a moderate antiviral effect of molnupiravir [23]. In the UK-based PANORAMIC trial involving more than 25,000 participants, the addition of molnupiravir to usual care for vaccinated adults in the community with confirmed COVID-19 and at increased risk of adverse outcomes was associated with reduced time to recovery overall and for key individual symptoms, reduced healthcare seeking for some primary care services, and reduced viral load [24]. The US Food and Drugs Administration (FDA) granted an Emergency Use Authorization (EUA) in 2021 for molnupiravir in adults with mild-to-moderate COVID-19 who are at high risk of developing a severe infection and who either cannot access or are deemed clinically inappropriate for alternative COVID-19 treatment options [25].

The oral antiviral paxlovid consists of nirmatrelvir (an irreversible inhibitor of the SARS-CoV-2 Mpro) and ritonavir. About 90% of people are protected from severe COVID-19 and hospitalization if paxlovid treatment starts in the first few days after symptoms appear. Interestingly, evolutionary mutations can occur that affect the Mpro gene, but do not appear to alter the antiviral potency of nirmatrelvir [26].

While these antivirals are expected to reduce hospitalizations and deaths among patients with COVID-19, new virus variants continue to emerge with mutations that may provide SARS-CoV-2 with the ability to evade immunity, fueling future waves of infection and diminishing treatment options. The world urgently needs therapeutic strategies capable of attacking SARS-CoV-2 from multiple aspects.

The global development of CAMs against COVID-19

Due to the various challenges posed by COVID-19, governments, healthcare professionals and pharmaceutical companies are investing enormous efforts to control the disease worldwide. The scientific community is experimenting with new interventions [27]. Countries with a long history of traditional medicine such as China, India and Taiwan are exploring the effectiveness of their traditional medicines in the treatment of COVID-19.


TCM is recommended in China by the National Health Commission (NHC) guidelines for the treatment of COVID-19 [9]. The TCM concept of personalized treatment through syndrome differentiation enables clinicians to summarize pathological bodily signs during the disease course, based on diagnostic data collected from patients via observation, listening and smelling, asking, palpation and pulse‐taking [28].Footnote 1

Up until February 2023, 15 TCMs are recommended in China for the treatment of COVID-19: seven oral formulations (Angong Niuhuang, Zixue, Huoxiang Zhengqi, Jinhua Qinggan, Lianhua Qingwen, Shufeng Jiedu, and Fangfeng Tongsheng) and eight injectable formulations (Xiyanping, Xuebijing, Reduning, Tanreqing, Xingnaojing, Shenfu, Shengmai, and Shenmai). The China Food and Drug Administration (CFDA) has approved Xuebijing for treating new coronavirus pneumonia with severe and critical systemic inflammatory response syndrome or/and multiple organ failure, and Lianhua Qingwen for treating fever, cough, and fatigue caused by the light and ordinary types of the new coronavirus pneumonia [29, 30]; each TCM formulation consists of several active ingredients with multitarget effects that are intended to counteract drug resistance. In particular, two TCM formulations (the Reyanning mixture and Jingyin granules) have shown potent anti-inflammatory and immunomodulatory effects [31, 32]. China is now conducting many clinical trials assessing the effectiveness of various TCM formulations for the treatment of COVID-19.


In view of the contagiousness and severity of COVID-19 infection, India’s Ministry of AYUSH (Ayurveda, Yoga and Naturopathy, Unani, Siddha and Homeopathy) recommends a decoction of ginger, curcumin, cloves, honey, fennel seeds, cumin seeds in warm water as an immune booster [33]. Nonpharmacologic Ayurvedic preventive measures include a healthy lifestyle, adequate physical activity, adequate sleep, and avoidance of patients with COVID-19. Ayurvedic medicines including garlic (Allium sativum L.), turmeric (Curcuma longa L.), carom or ajwain (Trachyspermum ammi L.) can be used to prevent COVID-19 [34]. Numerous studies in India have reported antiviral properties of Ayurvedic preparations in COVID-19 treatment. In vitro evidence shows that Withania somnifera (Ashwagandha), Tinospora cordifolia (Giloy) and Ocimum sanctum (Tulsi) demonstrate protease inhibitory activity against SARS-CoV-2 [35]. The WHO supports Artemisia annua (abundant in India and China) as a drug research candidate for treating COVID-19 [36, 37].


The Department of TCM of the Ministry of Health and Welfare of Taiwan encourages TCM clinical services for treating COVID-19 [38]. The Chinese medicine formulations Jing Si Herbal Tea, Jing Guan Fang, Taiwan Chingguan Yihau (NRICM101) and NRICM102 that have been launched since 2020 have all been developed and applied in Taiwan and show promise in the treatment of COVID-19 (Table 1).

Table 1 Possible therapeutic effects of the Chinese medicine formulations in COVID-19 treatment

Jing Si herbal drink

Jing Si herbal drink (JSHD), a formula jointly developed by Tzu Chi University and Tzu Chi Hospital in Taiwan, contains a total of eight medicinal materials. The ingredients of JSHD include Artemisia argyi (21.28%), Anisomeles indica (21.28%), Houttuynia cordata (14.18%), Platycodon grandifloras (14.18%), Ophiopogon japonicus (14.18%), Perilla frutescens (7.09%), Glycyrrhiza glabra (7.09%), Chrysanthemum morifolium (0.71%) (Table 1). In the treatment of COVID-19 infection, JSHD shows good antiviral activity (blocking angiotensin converting enzyme-2 [ACE2], transmembrane protease, serine 2 [TMPRSS2] and 3C-like protease [3CLpro] activity), antioxidant activity (increasing superoxide dismutase (SOD) activity), anti-inflammatory activity (decreasing inducible nitric oxide synthase [iNOS] expression and nuclear factor-κB [NF-κB] phosphorylation, inhibiting nitric oxide [NO], tumor necrosis factor-α [TNF-α] and interleukin 6 [IL-6] production), suppression of immune system overactivity (reducing macrophages, neutrophils, and leukocytes), and attenuation of organ damage [39]. JSHD shows potential for the inhibition and treatment of COVID-19, although further studies are needed to evaluate possible interactions between JSHD and Chinese herbal components in different pathways, as well as the effects of different drugs on the pharmacologic activities of JSHD. For now, this formulation is deemed appropriate as an adjunctive agent in the COVID-19 treatment armamentarium. More clinical evidence is awaited as to the efficacy and safety of JSHD in COVID-19 infection [40].

Jing Guan Fang

Jing Guan Fang (JGF) is the product of a research team led by Dr. Xu Zhonghua from the Yangming Jiaotong University Institute of Traditional Medicine and Taipei City Hospital. This research team designed JGF with reference to TCM theory described in the ancient medical classic “Wen Epidemic”. JGF consists of five herbs: Forsythia suspensa (Thunb.) Vahl (monarch), Scutellaria baicalensis (minister), Bupleurum Chinese (adjuvant), Magnolia officinalis Rehder and E.H. Wilson (adjuvant) and Agastache rugose (Fisch. and C.A. Mey.) Kuntze (courier) [41].

JGF inhibits syncytia and viral plaque formation and has not shown toxicity in cellular and preclinical studies [41]. JGF has induced the degradation of lysosome-dependent ACE2 and suppressed levels of TMPRSS2 mRNA and protein in human lung WI-38 and MRC-5 cells, and lowered protein levels of ACE2 and TMPRSS2 in lung tissues of mice after inhaling JGF [41]. These findings suggest that JGF has potential as an adjunctive preventive strategy against SARS-CoV-2 infection [41].

Taiwan Chingguan Yihau

NRICM101 was developed in 2020 by Taiwan’s National Research Institute of Chinese Medicine (NRICM) for alleviating mild and moderate cases of infectious pneumonia. The dosage of NRICM101 is increased or decreased according to “mild decoction pieces” (for details, refer to the NRICM instruction manual:,r61.php?Lang=en). NRICM101 originates from the “Jing Fang Baidu Powder” TCM formula detailed in “The Prescriptions for Taking Lives” compiled by Zhang Shiche during the Ming Dynasty. The original recipe contains Nepeta, Fangfeng, bupleurum, poria, platycodon, Chuan Xiong, Qiang Huo, Duhuo, Citrus aurantium, licorice, ginger, and other medicinal materials. As the main clinical manifestations of patients with novel coronavirus disease consist of “disease entering the lung and transforming heat”, the prescription has been adjusted to use “Nepeta, Fangfeng, Mint, Mulberry Leaf” as the monarch medicine, “Scutellaria baicalensis, Radix isatidis, Houttuynia cordata” used as ministerial medicines, “Quan Gulou” for chest and an expectorant and “Hopu” for lowering qi and relieving asthma are used as adjuvant medicines, while “Licorice” is used as agent to reconcile the entire recipe [13, 14]. Thus, the ingredients of NRICM101 are mint, nepeta, mulberry leaf, parsnip, skullcap, Houttuynia cordata, northern isatis root, cogongrass, magnolia bark, and licorice.

At the time of writing this review, 14 GMP Chinese medicine factories have obtained authorization for the manufacture of NRICM101; 12 products prepared by these GMP factories have been granted a special drug license for export and a temporary drug license (EUA) by Taiwan’s Ministry of Health and Welfare, and the rights to produce and export to almost 60 countries worldwide that have experienced severe COVID-19 epidemics (including Europe, America, Asia, Africa and Australia) [42]. NRICM101 has successively obtained the following import rights: the “Singapore Drug Certificate”, “Australian Drug Certificate”, “Thailand Herbal Medicine License”, “EU Supplementary Food Registration Certificate”, “Philippine Herbal Medicine Granule Registration”, “Cambodia Dietary Supplement Registration”, “UK Import Permit”, “US Import Permit”, “Canada Import Permit”, and the “South Africa Import Permit”.

Studies of NRICM101 have demonstrated multiple targeting mechanisms, including the blockade of the COVID-19 spike protein receptor-binding domain by binding to the host cell's ACE2 receptor and inhibiting viral infection, inhibiting 3CLpro activity and blocking host cell viral replication, inhibiting alveolar macrophages that secrete proinflammatory cytokines (TNF-α and IL-6) and thus stopping the formation of cytokine storms, reducing lung injury and the development of pulmonary fibrosis. The experience with NRICM101 in Taiwan suggests that this multitargeted drug candidate has good safety and therapeutic efficacy in COVID-19 [13, 14].

Taiwan Chingguan Erhau

NRICM102 was developed by Taiwan’s NRICM in 2021 and has been clinically tested for the adjuvant treatment of severely and critically ill patients with COVID-19. NRICM102 is derived from NRICM101 by adding or subtracting five herbs (Table 2) [13]. The antiviral and immune-regulating drugs remain unchanged, while the drugs for enhancing and repairing human tissue have been added. While NRICM101 is formulated for patients with mild and moderate new coronary pneumonia who are classified as below WHO grade 4 (no oxygen treatment required), NRICM102 is intended for severe-to-critically ill patients with new coronary pneumonia and a WHO clinical classification of grade 5 or above (oxygen therapy is required) [14, 15].

Table 2 Comparison of the medicinal ingredients in NRICM101 and NRICM102 [13, 15]

The formula of NRICM102 is composed of 10 herbs, including Scutellaria baicalensis, Houttuynia cordata, Trichosanthes, Pao Fuzi, Magnolia officinalis, poria, Polygonatum, Pinellia sinensis, Mian Yin Chen and Zhi Gan Cao (Table 3). NRICM102 has proven effective in improving pulmonary fibrosis in animal experiments, and good results have also been found in preliminary clinical trials exploring the same therapeutic indication [14, 15]. Studies have shown that NRICM102 has five major effects: inhibiting the activity of SARS-CoV-2 virus; immunomodulatory activity—inhibiting spike protein-induced cytokine expression activity; inhibiting acute lung inflammation injury activity; pulmonary embolism screening protection activity; prevention and improvement of lung fibrotic potential.

Table 3 Overview of NRICM101 and NRICM102 ingredients and the therapeutic efficacies of each ingredient

Therapeutic efficacy of NRICM101 and NRICM102 in COVID-19 treatment

Data from studies and mechanisms of action for all NRICM101 and NRICM102 compounds and their active constituents are described in detail below and summarized in Table 4.

  1. 1.

    Mulberry leaf (Morus alba L.)

    Mulberry leaves are one of the most commonly used Chinese herbal medicines and are an excellent source of functional nutraceuticals. The traditional usage is to treat wind-cold headache, dizziness, cough, bronchitis and asthma. Mulberry leaf has many biological activities such as antioxidant, antibacterial, anti-inflammatory, hypoglycemic, and anti-aging [43]. Kuwanon X from M. alba leaf have shown anti-infective activities, particularly against herpes simplex virus 1 (HSV-1), herpes simplex virus 2 (HSV-2) replication and inhibited the HSV-1-induced nuclear factor (NF)-κB activation [44]. M. alba aqueous extract has exhibited activity against influenza viruses (H1N1 and H3N2) [45]. Notably, M. alba extract was found to block SARS-CoV-2 cell entry by inhibiting biological processes required for TMPRSS2 using molecular dynamics simulations [46]. Mulberry leaf flavonoids inhibited the production of inflammatory cytokines and decreased expression of NO, iNOS, cyclooxygenase-2 (COX-2) in lipopolysaccharide (LPS)-stimulated RAW264.7 cells [47].

  2. 2.

    Saposhnikovia root (Saposhnikovia divaricata (Turcz. ex Ledeb.) Schischk.)

    S. divaricata is a perennial herb native to northern Asia. Traditional Chinese medicine is used for dizziness, headache, and body aches. S. divaricata has been found to have inhibitory effects on peptic ulcer, reduce fever, and possess analgesic, antioxidant and anti-inflammatory activities [48]. Some evidence suggests that three new coumarins from S. divaricata inhibits porcine epidemic diarrhea virus (PEDV) activity [49]. Ethanol extracts of S. divaricata showed antiinflammatory and antiosteoarthritis effects reduced the LPS-induced NO, prostaglandin E2 (PGE2), TNF-α, and IL-6 in RAW 264.7 cells [50].

  3. 3.

    Indigowoad root (Isatis tinctoria subsp. tinctoria)

    During the SARS outbreak in China, Hong Kong, and Taiwan, I. indigotica were often used to prevent SARS. I. indigotica root has been found to have antiviral effects against influenza, hepatitis A, and Japanese encephalitis. I. Indigo root contains indigo, indirubin, indigo (indoxyl-β-d-glucoside), β-sitosterol, γ-sitosterol and sinigrin [51]. Indigo, sinigrin, aloe-emodin, and hesperetin were found in I. indigotica roots to show anti-influenza virus effects by blocking 3CLpro cleavage [52]. Lariciresinol from I. indigotica inhibits hepatitis B virus by regulating viral transcription [53]. The petroleum ether extract of I. indigotica showed anti-inflammatory properties by downregulating inflammatory cytokines such as IL-6 and interleukin-33, inhibiting mast cell responses, and COX-2 activity in a murine model [54].

  4. 4.

    Peppermint herb (Mentha canadensis L.)

    M. canadensis is widely used in food, cosmetics and pharmaceuticals. In Chinese medicine, M. canadensis is used to treat diseases related to the nervous, respiratory, reproductive and digestive systems. Pharmacological studies of M. canadensis revealed antibacterial, anti-inflammatory, antiviral, antioxidant, antitumor, antidiabetic, cardioprotective and hepatoprotective activities, mainly due to its antioxidant potential as well as low toxicity and high efficacy results [55]. M. canadensis contains many volatile compounds (such as menthol and menthone) as well as polyphenolic acids, flavonoids and monoterpenoids [55]. Furthermore, M. canadensis effectively prevents disease development in a SARS-CoV-2-infected hamster disease model [56]. M. arvensis essential oil exerts anti-inflammatory in LPS-stimulated inflammatory responses via inhibiting inflammatory cytokines and extracellular signal regulated kinase (ERK)/NF-κB signaling pathway and anti-atopic dermatitis-like effects in 2,4-dinitrochlorobezene-induced mice [57].

  5. 5.

    Nepeta tenuifolia (Schizonepeta tenuifolia Briq.)

    N. tenuifolia has a long history of medicinal use in China, Taiwan, Japan, and Korea. It is traditionally used in the treatment of fever, headache, viral infections, and sore throat, and has anti-inflammatory, immunomodulatory, antioxidant, and antipruritic activities [58]. The main chemical constituents of N. tenuifolia are volatile oils, with isomenthone and menthone being the two most abundant constituents [58]. S. baicalensis extracts inhibited virus replication through the induction of antiviral interferon production [59, 60]. The anti-inflammatory effects of an aqueous extract of N. tenuifolia on LPS-induced TNF-α and IL-6 in vivo and in vitro [61].

  6. 6.

    Scutellaria root (Scutellaria baicalensis Georgi)

    For TCM purposes, S. baicalensis is used to clear heat, purge fire, detoxify, and achieve hemostasis. S. baicalensis has shown antitumour, antiviral, antimicrobial, and anti-inflammatory activities [62]. S. baicalensis extracts are active against Zika, influenza A (H1N1), human immunodeficiency virus (HIV) and dengue virus (DENV) viruses. Flavonoid ingredients (baicalin, baicalein and wogonin) in S. baicalensis inhibit the in vitro replication of SARS-CoV-2 and 3CLpro [62, 63], and significantly lower NO production and levels of TNF-α, IL-6, and monocyte chemoattractant protein-1 (MCP-1) expression [64]. S. baicalensis water extract significantly inhibits NO production, interleukins 3, 6, 10, 12p40 and 17, interferon-inducible protein-10 (CXCL-10), vascular endothelial growth factor (VEGF) and keratinocyte-derived chemokines in LPS-stimulated RAW 264.7 macrophages [65].

  7. 7.

    Yuxingcao (Houttuynia cordata Thunb.)

    H. cordata has traditionally been used to treat pneumonia, bronchitis, and chronic obstructive respiratory disease. Scientific analysis has identified antiviral, anti-inflammatory, and antioxidative activities in H. cordata extract [66]. H. cordata is also active against herpes simplex virus 1 (HSV-1), influenza virus, and HIV type 1 (HIV-1) [67, 68].

    H. cordata essential oil inhibits COX-2, while H. cordata aqueous extracts reduce influenza symptoms and LPS-induced lung injury [69]. The H. cordata flavonoid quercitrin shows anti-inflammatory activity [70] and reduces cell numbers in the bronchoalveolar fluid of mice with LPS-induced lung injury [71]. Quercitrin also helps to prevent body weight loss, reductions in viral titers and mortality in mice infected with influenza A/WS/33 virus [72].

  8. 8.

    Gancao (Glycyrrhiza uralensis L.)

    The most important medicinal parts of G. glabra L. (Fabaceae family), commonly known as licorice, are the rhizomes and roots, which are used alone or in combination with other herbs to treat digestive system disorders (e.g., stomach ulcers, hyperdipsia, flatulence, colic), respiratory tract disorders (e.g., asthma, coughs, sore throat, and tonsillitis), jaundice, hemorrhagic diseases, malaria, fever, epilepsy, sexual dysfunction, paralysis, rheumatism, leucorrhea, psoriasis, and prostate cancer. Licorice is used as a food and beverage flavoring [73].

    The active compounds in G. glabra roots include the flavonoids glucoliquiritin, licoarylcoumarin, licopyranocoumarin, liquirtin, liquiritigenin, isoliquiritigenin, rhamnoliquirilin, and glycyrrhizin. Notably, glycyrrhizin can inhibit virus-cell binding and has proven efficacy in HIV-1 and chronic hepatitis C virus (HCV) infections [74]. Glycyrrhizin markedly inhibits SARS viral reproduction [75, 76]. Both glycyrrhizin and isoliquiritigenin effectively suppress LPS-induced activation of signaling cascades and cytokine production [77].

  9. 9.

    Houpo (Magnolia officinalis Rehder & E.H. Wilson)

    M. officinalis contains several biologically active compounds: 4-O-methylhonokiol, honokiol, magnolol, obovatol, and other neolignan compounds. In particular, honokiol and magnolol exhibit antitumorigenic, anti-inflammatory, antithrombotic, antioxidative, and neuroprotective activities [78]. M. officinalis extract suppresses human norovirus surrogates, murine norovirus (MNV) and feline calicivirus (FCV) in vitro and reduces MNV and FCV titers to undetectable levels in model food systems [79]. Honokiol can also inhibit furin-like and SARS-CoV-2 infection activity [80]. In a mouse model of pneumonia, treatment with polyphenol-rich extract from M. officinalis bark lowered high levels of NO, IL-6 and TNF-α expression and provided long-term protection against reinfection [81, 82].

  10. 10.

    Gualou (Trichosanthes kirilowii Maxim.)

    T. kirilowii tuber extract has long been used in Eastern Asian medicine to alleviate diabetes symptoms. Cucurbitacin D has been isolated from T. kirilowii and has shown anti-inflammatory and anticancer activities. Cucurbitacin D induces apoptosis and suppresses tumor cell proliferation by inhibiting signal transducer and activator of transcription 3 (STAT3) and phosphorylating NF-κB [83, 84]. Trichosanhemiketal A and B from T. kirilowii inhibit iNOS and COX-2 expression [85]. T. kirilowii trichosanthin extract inhibits HIV-1 replication and displays antitumor activity [86].

  11. 11.

    Yinchen (Artemisia scoparia)

    A. scoparia is used for hepatoprotective, choleretic, and diuretic effects. Scientific evidence suggests wide-ranging in vivo and in vitro biological activity of A. scoparia extracts and active constituents, covering anticancer, anti-inflammatory, antibacterial, hepatoprotective, anti-atherosclerotic, antiviral and neuroprotective functions. A. scoparia total flavonoids suppress the production of NO, ROS, TNF-α, IL-6, MCP-1 and prostaglandin E2 (PGE2) and strongly inhibit the degradation of nuclear factor kappa B α (IκBα) as well as the nucleus translocations of phosphoryl-p65, p-p38 and phosphate- extracellular signal regulated kinase 1/2 (p-ERK) in RAW264.7 cells after LPS stimulation [87]. A. scoparia total flavonoids also decrease the lung wet: dry weight ratio in lung tissue specimens from mice with acute lung injury [87]. A. scoparia water extract has potent anti-inflammatory activity in macrophages and alleviates carrageenan-induced acute inflammation in mice [88]. Scopolein, a coumarin isolated from A. scoparia, suppresses the production of proinflammatory cytokines and inhibits LPS-induced PGE2 production by reducing COX-2 expression [89]. Scopoletin also ameliorates synovial inflammation and lessens the destruction of cartilage and bone in rats with adjuvant arthritis by reducing IL-6 expression and inhibiting the phosphorylation of p38 mitogen-activated protein kinase, ERK, and protein kinase C (PKC) [90]. The A. scoparia flavonoid cirsimaritin can reduce influenza virus A (IAV) viral titers and protein synthesis by inactivating the NF-κB/p65 signaling pathway [91]. Around 90% of A. scoparia ethanol extracts exhibit anti-hepatitis B virus (HBV) activity [92], while other important compounds isolated from A. scoparia exhibit inhibitory effects on coronoviruses. Notably, another flavonoid compound isolated from the Artemisia genus, isorhamnetin, inhibits the activity of SARS-CoV-2 spike pseudotyped virus via the binding of ACE2, indicating that isorhamnetin may have therapeutic potential against COVID-19 [93].

  12. 12.

    Fuling (Wolfiporia extensa)

    Wolfiporia extensa is an edible medicinal mushroom that is used in the treatment of edema, insomnia, spleen deficiency, vomiting, and other diseases. Edible mushrooms have recently been used as functional foods or dietary supplements. Pharmacological effects of W. extensa include antitumor, antioxidant, anti-inflammatory and antibacterial activities, immunomodulatory effects and immune enhancement. Polysaccharides have strong antitumor and hepatoprotective effects. Polysaccharides and triterpenes are the main biologically active compounds of W. extensa [94]. Pachymic acid and dehydrotumulosic acid isolates from W. extensa have inhibited acute ear edema, which indicates considerable anti-inflammatory potency [95]. A 50% hot ethanol extract from W. extensa dose-dependently increased the in vitro secretion of IL-1β and IL-6 in human peripheral blood monocytes [96], while Fuling polysaccharide has stimulated RAW264.7 macrophages via the induction of TNF-α and IL-1β and the regulation of NF-κB-related gene expression [97].

  13. 13.

    Yuzhu (Polygonatum odoratum)

    P. odoratum has shown strong clinical efficacy in the treatment of diabetes, microbial infections, inflammation, and tumors. P. odoratum and its main constituents scutellarein-7-glucoside and quercitrin are associated with reduced IL-6 secretion in LPS-stimulated macrophages [98]. Three anthraquinone analogues have been isolated in phytochemical research involving ethyl acetate-soluble ingredients extracted from the roots of P. odoratum [99]. Polysaccharides from P. odoratum promote the proliferation and neutral red phagocytosis of RAW 264.7 macrophages [100].

  14. 14.

    Banxia (Pinellia ternata)

    P. ternata is extremely effective in the treatment of cough, vomiting, infection, and inflammatory diseases. P. ternata contains many alkaloids, iridoids, iridoid glycosides, anthraquinones, anthraquinone glycosides, fatty acids and their derivatives. Pharmacologic investigations have shown that P. ternata has antidepressant, wound healing, antitussive, antiemetic, antifungal, anti-inflammatory, sedative-hypnotic, antioxidant and insecticidal activities [101]. P. ternata also inhibits cancer cell proliferation and convulsive seizures [101]. In rats with chronic obstructive pulmonary disease, P. ternata treatment reversed the increases in IL-1β and TNF-α levels in bronchoalveolar lavage fluid (BALF) after budesonide withdrawal and protected the airway from mucus hypersecretion and airway inflammation after inhaled corticosteroid withdrawal [102].

    In a mouse model of allergic asthma, P. ternata water extract significantly attenuated the ovalbumin (OVA)-induced influx into the lungs of total leukocytes, eosinophils, neutrophils, macrophages and lymphocytes, and dose-dependently reduced the levels of IL-4, IL-13 and TNF-α [103]. P. ternata water extract also significantly reduced the plasma levels of total and OVA-specific immunoglobulin (Ig)E release into the airspace and inhibited OVA-induced increases in MUC5AC (mucin 5AC, oligomeric mucus/gel-forming) and iNOS expression [103].

  15. 15.

    Fuzi (Aconitum carmichaelii)

    For more than 2000 years, Fuzi (the lateral root of A. carmichaeli) has been used for its anti-inflammatory, analgesic and cardiotonic effects, and is mainly used in TCM to treat musculoskeletal disorders. Fuzi contains the highly toxic C19 diterpenoid alkaloids aconitine, mesaconitine and hypaconitine. Fuzi ingestion can result in typical signs and symptoms of aconitine poisoning. Ventricular arrhythmias can lead to death, most likely within the first 24 h. Cases of poisoning are still reported in areas where herbal medicine is used, including China, Taiwan, and India [104]. Using these toxic drugs may sound dangerous. However, A. carmichaeli has an important role in many diseases, including rheumatism, arthralgia, edema, gastroenteritis, asthma, abdominal pain, and some gynecological diseases such as irregular menstruation and dysmenorrhea [105]. Moreover, A. carmichaeli is a very effective pain reliever herb due to its action upon neuronal cells [105]. Therefore, it is important to study its effects, toxicity and therapeutic relevance in depth. The processed product of A. carmichaeli reduces serum TNF-α and IL-β levels in the rat adjuvant arthritis model [106]. Crude Fuzi combined with glycyrrhiza reduces the risk of heart failure by ameliorating the inflammatory response, which researchers suspect could be partly related to the inhibition of the Toll-like receptor-4 (TLR4)/NF-κB action in the heart [107].

Table 4 The potential efficacy of the herbs of NRICM101 and NRICM102 used as adjunctive therapies in COVID-19 infection

TCM for clinical management of COVID-19 in Taiwan

Currently, four TCM formulations intended for use against COVID-19 have been subjected to clinical research in Taiwan and the published data are providing policymakers and healthcare personnel with the opportunity to prepare for future epidemics in Taiwan (Table 1).

Clinical efficacy of Jing Si Herbal Tea in Taiwan

In this study, 260 patients with mild-to-moderate COVID-19 infection were allocated to the JSHT group (n = 117) or control group (n = 143), in combination with standard management. JSHT therapy was associated with reductions in SARS-CoV-2 viral load, systemic inflammatory markers (IL-6, IL-8, and IL-10), and lung infiltrates, especially in male and elderly patients (aged ≥ 60 years). Mortality rates were 0.0% in the JSHT group and 2.8% in the control group, indicating that JSHT combined with standard management may prevent the development of critical illness and mortality in patients with mild-to-moderate COVID-19 [39, 40].

Clinical efficacy of Jing Guan Fang in Taiwan

Responses have been analyzed from 396 Taiwanese patients (mean age 45.9 years; 35.1% male, 64.9% female) with COVID-like symptoms who completed a questionnaire about their experiences of JGF administered as a complementary preventative strategy. Sore throat was the most common COVID-19-like symptom, affecting 34 patients; at 7 days after consuming JGF, 31 (91.2%) of those patients reported an improvement in symptoms. Similarly, among patients who reported non-COVID-19-like symptoms of fatigue (n = 128) and nervousness (n = 102), the majority reported improvements in these symptoms at 7 days after taking JGF (81.3% and 68.6%, respectively) [41].

Clinical efficacy of NRICM101/102 in Taiwan

Data have been analyzed from 840 patients with COVID-19 infection admitted to 9 hospitals in Taiwan during 2021. The 2 study cohorts consisted of 302 patients (151 received NRICM101 and 151 did not) and 246 patients (123 received NRICM102 and 123 did not). During the 30-day observation period, patients who received NRICM101 plus usual care had no end point events, while 14 (9.27%) in the usual care group were intubated or admitted to the intensive care unit (ICU). Seven deaths (5.69%) occurred in the NRICM102 plus usual care group compared with 27 (21.95%) in the usual care group. Patients who did not receive NRICM101 transitioned to more severe states; NRICM102 users were 74.07% less likely to die than non-users. The data support the therapeutic efficacy of NRICM101 and NRICM102 in addition to usual care. NRICM101 and NRICM102 represent therapeutics with broad-spectrum active compounds that inhibit host cell pathways necessary for viral infection and replication and help to maintain bodily function to counter the effects of viral diseases. Both formulations have inhibitory effects on the five main variants of COVID-19 (Alpha, Beta, Gamma, Delta and Omicron), which addresses concerns about the evolution of the virus. This study provides important information about the adoption of oral therapy and evidence in support of NRICM101 and NRICM102 shortening response times to epidemic outbreaks, offering the potential for novel, safe treatments for future epidemics [13, 14].

Theoretical perspectives on herb-herb combinations

Many theories around the therapeutic concepts of TCM draw upon philosophical ideas such as the balance of yin and yang [108]. TCM seeks to establish that diseases develop in response to imbalances in various parts of the body, and that the use of herbal remedies and other therapeutic modalities, such as acupuncture and physical manipulations, can restore a state of balance. A set of TCM systems guides the clinician’s selection of medicines for the treatment of diseases [109]. Most TCM prescriptions contain more than one medicine, forming a multi-item mixture (compound). When prescribing medicines, clinicians must consider the principles of interaction between herbs in order to formulate the best prescription for therapeutic effect [110]. Combination effects, whether complementary or antagonistic, will be reflected in clinical outcomes [111, 112].

The compatibility theory of Chinese herbal medicine endorses the combination of more than one drug, according to the needs of the disease. The compatibility theory provides Chinese medicine with guiding principles for improving the safe and effective use of herbal medicines. This theory was first recorded in “Shen Nong’s Materia Medica”, a classic work that describes TCM [113]. From a modern pharmacologic point of view, this is a theory of herbal interactions. A total of seven possible outcomes refer to a single effect: mutual accentuation; mutual enhancement; mutual counteraction; mutual suppression; mutual antagonism; and mutual contrariness; all of which describe the interactions between drugs [114, 115].

“Eighteen Antagonisms” are representatives of incompatibility in clinical records of TCM. This is a special regulation for the compatibility of traditional Chinese medicine prescriptions, because mutual antagonism can lead to adverse reactions. Clinicians are most concerned with “contradictory” reactions, as this may involve clinical “adverse drug reactions”. Most Chinese medicine practitioners endorse the “eighteen antis” as a clinically recognized taboo, which dictates that a total of 18 substances across three groups of medicines should be avoided in combination to prevent increases in toxic and side effects [113]. However, famous physicians in ancient times often issued prescriptions that violated the eighteen antis [114, 116]. For example, Zhang Zhongjing’s “Essentials of the Golden Chamber” included “Gansui Banxia Decoction”, which combines gansui and licorice [117, 118]. Some medical experts also believe that medicinal use of mutually contrary drugs can complement each other and produce strong effects. If used properly, such medicinal use can cure some clinical conditions. Thus, some clinicians believe that clinical medicine should not be limited to the “eighteen antagonisms”.

Pharmacological research on the synergism among Aconitum carmichaeli, Trichosanthes kirilowii, and Pinellia ternate

The mixed use of A. carmichaeli, T. kirilowii and P. ternate in NRICM102 violates the TCM compatibility (“eighteen antagonisms”) principle and may produce or enhance toxic reactions or side effects [15] (Table 5).

  1. 1.

    The compatibility of A. carmichaeli and T. kirilowii

    The “eighteen antagonisms” specifies that A. carmichaeli and T. kirilowii should not be used together, although scant evidence supports this dictum. The main functions of aconite are to restore and assist yang in relieving inferiority, dispel cold to relieve pain, and to treat diseases such as heart failure and wind-cold-dampness arthralgia. The therapeutic effects of T. kirilowii include the clearing away of heat and expectoration of phlegm, widening of the chest and dispelling of knots, moisturizing dryness and smoothing the intestines [119]. Although A. carmichaeli and T. kirilowii are considered anti-drugs and there are contraindications for compatibility, some historical records indicate that the two can be used together for treatment of disease. There are also examples of modern medicine using these substances in combination. A. carmichaeli and T. kirilowii have been commonly used in TCM for the treatment of heart disease since the time of Zhang Zhongjing during the Han Dynasty. From the perspective of TCM for the treatment of heart failure, aconite and cinnamon sticks are appropriate for patients with yang deficiency, while melon wilt and the like are added for patients with yang deficiency and phlegm turbidity. This method is consistent with the TCM theory of warming yang and removing turbidity [120]. In rats with chronic pressure-overload heart failure in the early stage, the combination of the dried tuber of A. carmichaeli and T. kirilowii appears to be beneficial [121], whereas the same therapeutic combination appears to aggravate heart and kidney inflammation and promote myocardial fibrosis in rats with middle- or late-stage chronic heart failure [122]. More research is needed to confirm this.

  2. 2.

    The compatibility of A. carmichaeli and Pinellia ternate

    A review of the ancient and modern literature, combined with an investigation of clinical prescriptions, reveals a large body of evidence showing that the combination of Fuzi and Pinellia in the treatment of heart failure, chest tightness and pain synergistically enhances efficacy and reduces toxicity. In these therapeutic indications, the function of TCM is to restore yang and relieve inversion, tonify fire and assist yang, and eliminate wind, cold and dampness. Preprocessed aconite contains a large amount of aconitine, which will cause cardiac paralysis that in turn causes death; processed aconite is less toxic. Fuzi, one of the oldest and most commonly used TCM substances for treating heart failure, exhibits many pharmacological effects, including cardiotonic, anti-inflammatory, analgesic and antitumor activities, and hemodynamic improvement [123]. The combination of aconite and Pinellia first appeared in the “Golden Chamber Synopsis”, in which the Fuzi Japonica Decoction was prescribed by Zhang Zhongjing to treat the symptoms of thunder and pain in the abdomen, chest and flank fullness and vomiting in the upper offenders of the internal resistance of yin, cold and dampness. This decoction consists of Pao Fuzi, Pinellia, licorice, jujube, and japonica. In the prescription, aconite tonifies yang and benefits fire, dispels cold and relieves pain. When yang is prosperous, the evil of yin cold and damp turbidity will be naturally eliminated. Sun Simiao’s “Qianjin Yaofang” from the Tang Dynasty records the use of Dawuyin Pills, while the official medical book “Taiping Huimin Mixture Jufang” from the Song Dynasty describes the use of the Shishiwei Jianzhong Decoction with aconite Pinellia. Thus, Fuzi and Pinellia in combination has potential for the treatment of various diseases.

    A statistical analysis of the “Chinese-Italian Dictionary of Prescriptions” records 502 classic prescriptions using both Fuzi and Pinellia. This combination can reduce the toxicity and improve the pharmacological effects of each substance. In animal models of chronic heart failure, Fuzi compatibility with other reviewed study treatments was superior to Fuzi alone for the treatment of chest tightness and pain and was associated with reduced toxicity [123].

    Pharmacologic research has found that the combination of aconite and Pinellia inhibits the β2-adrenergic receptor / stimulatory G protein / protein kinase A (β2-AR/Gs/PKA) signal, which may explain the anti-inflammatory effects, antifibrosis and improvement of cardiac function that occurs with this therapy, although other data have described how aconite combined with Pinellia aggravates doxorubicin-induced cardiomyopathy associated with the β2-AR activation of Gs, the stimulatory G protein for adenylyl cyclase [124]. It is important to recognize the existence of antagonistic pharmacologic effects within a single TCM substance that can result in different or opposite effects. For instance, the four compounds in aconite (talatizamine, 14-acetyl-latizamin, hetisine, and 14-benzoylnovine) can counteract doxyrubicin-induced heart failure [125], while aconitine in aconite can induce apoptosis in H9c2 cardiomyocytes [126]. Aconite also produces antagonistic chemical components that play a role in antiarrhythmic effects, such as N-aconitine, N-deacetylaconitrile, raconitine, aconitine, 14-acetyl taladiamine, and aconitine [127]. Thus, different active ingredient composition ratios of aconite and Pinellia may induce different or antagonistic effects from those originally intended.

  3. 3.

    The Compatibility of A. carmichaeli and Ampelopsis japonica

    A formula combining A. carmichaeli with A. japonica was first recorded in “Da Ba Feng San” by Sun Simiao (Tang Dynasty) in his “Qian Jin Fang” [128]. The TCM fumigation and washing method for the formula containing A. carmichaeli and A. japonica produces a significant curative effect in knee osteoarthritis, with a very high cure rate of 96.55% [129]. When arthritis is treated with these two herbs and others in combination with sodium hyaluronate, joint swelling has been eliminated, with accompanying pain relief [130]. A. japonica has therapeutic potential in the treatment of rheumatoid arthritis [131].

    The use of “eighteen antagonisms” drugs in prescriptions that may cause or aggravate known side effects is controversial and has prevented the clinical application of many TCM herbal combinations [119]. However, NRICM102 treatment of patients with COVID-19 has been associated with greatly reduced mortality rates compared with conventional medical treatment and no toxic reactions have been recorded with NRICM102; 1 patient death has occurred due to severe COVID-19 infection [15]. Moreover, 30-day toxicity test results from mice administered NRICM102 revealed no abnormal tissue or organ reactions [15].

    From the treatment perspective, patients with severe pneumonia complicated by cardiopulmonary failure who need to use aconite to enhance cardiopulmonary function usually also have pulmonary edema and hydropleural effusion and require Pinellia and Trichosanthes to clear the respiratory tract [100, 101]. Such patients have sputum in the pleural cavity, which is unlikely to be due to the toxic drug combination that ancient physicians believed to be contributing to the patient’s rapid clinical deterioration and death. Those physicians believed that (1) it is too late to reverse the disease pathogenesis and prevent rapid deterioration and (2) strong aconitine toxicity exists due to incomplete processing of aconitum. We believe that rigorous drug research and development, combined with diagnoses and treatments prescribed by professional and experienced clinicians, will support the combination of Fuzi, Pinellia and Trichosanthes for improved clinical efficacy and rescue patients in a timely manner [83]. Combinations of TCM substances and interactions between Chinese and Western medicine are important clinical issues that deserve full attention.

Table 5 Traditional knowledge of aconite unpaired in “eighteen antagonisms”


Although the Omicron mutant strain has greatly reduced the toxicity and lethality of COVID-19 infection, the COVID-19 epidemic continues to cause anxiety. For infected patients isolated at home, TCM can be used to prevent severe illness. Scientific evidence shows that TCM ingredients clear away heat and detoxify, remove moisture from the body’s surface and inhibit viruses. TCM can improve the symptoms of COVID-19, slow clinical deterioration, and reduce all-cause mortality in severe COVID-19 infection. The therapeutic efficacy of TCM may be improved by using different combinations of compounds. TCM antiviral activity occurs either through the direct inhibition of the entry and replication of the virus, with the use of substances such as Houttuynia and Scutellaria to clear heat and detoxify [132], or by indirectly exerting antiviral effects or inhibiting virus-mediated inflammatory responses by regulating the immune function of organisms. Licorice and mint are used as antivirals and induce interferon and immunoglobulin [10]. As TCM focuses on the overall regulation of the body, such therapy can play a multitargeted role in the regulation of body systems [133, 134]. Effecting a cure of a complex disease such as COVID-19 may not be possible with a single targeted drug, whereas the multicomponent and multitargeted nature of Chinese medicine suggests that such treatment has good potential to supplement standard medical treatment in COVID-19 [135, 136]. An important aspect of different Chinese medicines is that they may share the same or similar targets and pathways. Improving our understanding of how underlying mechanisms of action of TCM ameliorate symptoms of COVID-19 will help us to improve the use of TCM in the preventing and treating COVID-19 infection, help us to understand how molecular mechanisms associated with TCM can improve organ damage caused by COVID-19, and use modern scientific techniques to determine the material basis of possible drugs. This review is intended as a reference for the development of new drugs for preventing and treating viral infections such as COVID-19. NRICM102 is an herbal formula that has been developed according to TCM theory and preclinical experimental data. Mechanism of action studies reveal that the therapeutic effects of NRICM102 occur through the comprehensive regulation of multiple targets and multichannel synergistic mechanisms. While the global COVID-19 outbreak shows no sign of lessening, NRICM102 may be used in addition to conventional drug therapy for treating severe cases of infection.

Availability of data and materials

Not applicable.


  1. Palpation is usually performed by a healthcare practitioner and refers to the process of using one's hands to feel an object in or on the body to determine its size, shape, firmness, or location, especially while perceiving/diagnosing a disease or illness. Pulse-taking is another TCM method of disease diagnosis, whereby a TCM practitioner touches the pulse in different parts of the human body and observes the changes in pulse conditions. This technique is also known as cutting pulse, diagnosing pulse, pressing pulse, or holding pulse.



Coronavirus disease 2019


Severe acute respiratory syndrome coronavirus 2


Complementary and alternative medicines


World Health Organization


Traditional Chinese medicine


Variants of concern


Monoclonal antibodies


RNA-dependent RNA polymerase

3CLpro :

3C-like protease

Mpro :

Main protease


Food and drugs administration


Emergency use authorization


National health commission


China cood and drug administration


Ayurveda, yoga and naturopathy, unani, siddha and homeopathy


Jing Si herbal drink


Angiotensin converting enzyme-2


Transmembrane protease, serine 2


Superoxide dismutase


Inducible nitric oxide synthase


Nuclear factor-κB


Nitric oxide


Tumor necrosis factor-α


Interleukin 6


Jing Guan Fang


National research institute of Chinese medicine


Taiwan Chingguan Yihau


Taiwan Chingguan Erhau


Influenza A


Human immunodeficiency virus


Dengue virus


Monocyte chemoattractant protein-1


Interferon-inducible protein-10


Vascular endothelial growth factor




Herpes simplex virus 1




Hepatitis C virus


Murine norovirus


Feline calicivirus


Signal transducer and activator of transcription 3


Prostaglandin E2


Nuclear factor kappa B α


Phosphate- extracellular signal regulated kinase 1/2


Extracellular signal regulated kinase


Protein kinase C


Influenza virus A


Bronchoalveolar lavage fluid




Mucin 5AC, oligomeric mucus/gel-forming


Toll-like receptor-4


Intensive care unit

β2-AR/Gs/PKA signal:

β2-Adrenergic receptor/stimulatory G protein/protein kinase A signal


  1. Liu Y-X, Zhou Y-H, Jiang C-H, Liu J, Chen D-Q. Prevention, treatment and potential mechanism of herbal medicine for Corona viruses: a review. Bioengineered. 2022;13:5480–508.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Ding Y, Zeng L, Li R, Chen Q, Zhou B, Chen Q, et al. The Chinese prescription lianhuaqingwen capsule exerts anti-influenza activity through the inhibition of viral propagation and impacts immune function. BMC Complement Altern Med. 2017;17:130.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Hsu C-H, Lin H-H, Wang C-C, Jhang S. How to defend COVID-19 in Taiwan? Talk about people’s disease awareness, attitudes, behaviors and the impact of physical and mental health. Int J Environ Res Public Health. 2020;17:4694.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Mody V, Ho J, Wills S, Mawri A, Lawson L, Ebert MCCJC, et al. Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents. Commun Biol. 2021;4:93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the Treatment of Covid-19—Final Report. N Engl J Med. 2020; NEJMoa2007764.

  6. Yang L, Wang Z. Natural Products, alone or in combination with FDA-cpproved drugs, to treat COVID-19 and lung cancer. Biomedicines. 2021;9:689.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Wu D, Hou X, Xia Z, Hao E, Xie J, Liang J, et al. Analysis on oral medication rules of traditional Chinese medicine prescriptions for prevention of COVID-19. Chin Herb Med. 2021;13:502–17.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Yang K-L, Jin X-Y, Gao Y, Xie J, Liu M, Zhang J-H, et al. Bibliometric analysis of researches on traditional Chinese medicine for coronavirus disease 2019 (COVID-19). Integr Med Res. 2020;9: 100490.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Luo H, Gao Y, Zou J, Zhang S, Chen H, Liu Q, et al. Reflections on treatment of COVID-19 with traditional Chinese medicine. Chin Med. 2020;15:94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Qiu Q, Huang Y, Liu X, Huang F, Li X, Cui L, et al. Potential therapeutic effect of traditional Chinese medicine on coronavirus disease 2019: a review. Front Pharmacol. 2020;11: 570893.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Yang Y, Islam MS, Wang J, Li Y, Chen X. Traditional Chinese medicine in the treatment of patients infected with 2019-new coronavirus (SARS-CoV-2): a review and perspective. Int J Biol Sci. 2020;16:1708–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Jan J-T, Cheng T-JR, Juang Y-P, Ma H-H, Wu Y-T, Yang W-B, et al. Identification of existing pharmaceuticals and herbal medicines as inhibitors of SARS-CoV-2 infection. Proc Natl Acad Sci. 2021;118:e2021579118.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Tsai K-C, Huang Y-C, Liaw C-C, Tsai C-I, Chiou C-T, Lin C-J, et al. A traditional Chinese medicine formula NRICM101 to target COVID-19 through multiple pathways: a bedside-to-bench study. Biomed Pharmacother. 2021;133: 111037.

    Article  CAS  PubMed  Google Scholar 

  14. Tseng Y-H, Lin SJ-S, Hou S-M, Wang C-H, Cheng S-P, Tseng K-Y, et al. Curbing COVID-19 progression and mortality with traditional Chinese medicine among hospitalized patients with COVID-19: a propensity score-matched analysis. Pharmacol Res. 2022;184:106412.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Wei W-C, Liaw C-C, Tsai K-C, Chiou C-T, Tseng Y-H, Chiou W-F, et al. Targeting spike protein-induced TLR/NET axis by COVID-19 therapeutic NRICM102 ameliorates pulmonary embolism and fibrosis. Pharmacol Res. 2022;184: 106424.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Shang J, Wan Y, Luo C, Ye G, Geng Q, Auerbach A, et al. Cell entry mechanisms of SARS-CoV-2. Proc Natl Acad Sci. 2020;117:11727–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Saxena SK, Kumar S, Ansari S, Paweska JT, Maurya VK, Tripathi AK, et al. Characterization of the novel SARS-CoV-2 Omicron (B.1.1.529) variant of concern and its global perspective. J Med Virol. 2022;94(4):1738–44.

    Article  CAS  PubMed  Google Scholar 

  18. Tao K, Tzou PL, Kosakovsky Pond SL, Ioannidis JPA, Shafer RW. Susceptibility of SARS-CoV-2 omicron variants to therapeutic monoclonal antibodies: systematic review and meta-analysis. Microbiol Spectr. 2022;10(4): e0092622.

    Article  PubMed  Google Scholar 

  19. Zhong L, Zhao Z, Peng X, Zou J, Yang S. Recent advances in small-molecular therapeutics for COVID-19. Precis Clin Med. 2022;5(4):pbac024.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Wang Y, Anirudhan V, Du R, Cui Q, Rong L. RNA-dependent RNA polymerase of SARS-CoV-2 as a therapeutic target. J Med Virol. 2021;93(1):300–10.

    Article  CAS  PubMed  Google Scholar 

  21. Gordon CJ, Tchesnokov EP, Schinazi RF, Götte M. Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template. J Biol Chem. 2021;297(1): 100770.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Medicines and Healthcare products Regulatory Agency First oral antiviral for COVID-19, Lagevrio (molnupiravir), approved by MHRA [4 Nov 2021]; 2021.

  23. Khoo SH, FitzGerald R, Saunders G, Middleton C, Ahmad S, Edwards CJ, et al. Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Infect Dis. 2023;23(2):183–95.

    Article  CAS  PubMed  Google Scholar 

  24. Butler CC, Hobbs FDR, Gbinigie OA, Rahman NM, Hayward G, Richards DB, et al. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial. Lancet. 2023;401(10373):281–93.

    Article  CAS  PubMed  Google Scholar 

  25. U.S. Food & Drug Administration. FDA News Release. Coronavirus (COVID-19) update: FDA authorizes additional oral antiviral for treatment of COVID-19 in certain adults. [23 Dec 2021]; 2021.

  26. Vangeel L, Chiu W, De Jonghe S, Maes P, Slechten B, Raymenants J, et al. Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern. Antiviral Res. 2022;198: 105252.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271-280.e8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Wang S, Wang Y, Lu Y, Li J, Song Y, Nyamgerelt M, et al. Diagnosis and treatment of novel coronavirus pneumonia based on the theory of traditional Chinese medicine. J Integr Med. 2020;18:275–83.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Du H-Z, Hou X-Y, Miao Y-H, Huang B-S, Liu D-H. Traditional Chinese Medicine: an effective treatment for 2019 novel coronavirus pneumonia (NCP). Chin J Nat Med. 2020;18:206–10.

    PubMed  PubMed Central  Google Scholar 

  30. Qi F, Tang W. Traditional Chinese medicine for treatment of novel infectious diseases: current status and dilemma. Biosci Trends. 2021;15:201–4.

    Article  CAS  PubMed  Google Scholar 

  31. Xu X, Zhou S, Chen C, Li J, Wu H, Jin G, et al. Efficacy and safety of Reyanning mixture in patients infected with SARS-CoV-2 Omicron variant: a prospective, open-label, randomized controlled trial. Phytomedicine. 2023;108: 154514.

    Article  CAS  PubMed  Google Scholar 

  32. Chen B, Yu X, Lei Z, Huang W, Lyu H, Xu Y, et al. Clinical efficacy of Jingyin granules, a Chinese patent medicine, in treating patients infected with coronavirus disease 2019. Phytomedicine. 2023;108: 154496.

    Article  CAS  PubMed  Google Scholar 

  33. Xin S, Cheng X, Zhu B, Liao X, Yang F, Song L, et al. Clinical retrospective study on the efficacy of Qingfei Paidu decoction combined with Western medicine for COVID-19 treatment. Biomed Pharmacother. 2020;129: 110500.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Nayak D, Nahar K, Bhalerao R, Kaur L, Parveen T, Bhalla R, et al. Effectiveness of arsenicum album 30C in prevention of COVID-19 in individuals residing in containment zones of Delhi—a prospective, community-based, parallel cohort study. Homeopathy. 2022; s-0042-1745755.

  35. Girija PLT, Sivan N. Ayurvedic treatment of COVID-19: a case report. J Ayurveda Integr Med. 2022;13: 100329.

    Article  CAS  PubMed  Google Scholar 

  36. Balkrishna A, Bhatt AB, Singh P, Haldar S, Varshney A. Comparative retrospective open-label study of ayurvedic medicines and their combination with allopathic drugs on asymptomatic and mildly-symptomatic COVID-19 patients. J Herb Med. 2021;29: 100472.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Shree P, Mishra P, Selvaraj C, Singh SK, Chaube R, Garg N, et al. Targeting COVID-19 (SARS-CoV-2) main protease through active phytochemicals of ayurvedic medicinal plants—Withania somnifera (Ashwagandha), Tinospora cordifolia (Giloy) and Ocimum sanctum (Tulsi)—a molecular docking study. J Biomol Struct Dyn. 2022;40:190–203.

    Article  CAS  PubMed  Google Scholar 

  38. Su YC, Huang GJ, Lin JG. Chinese Herbal Prescriptions for COVID-19 management: special reference to Taiwan Chingguan Yihau (NRICM101). Front Pharmacol. 2022;13:928106.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Lu P-H, Tseng C-W, Lee J-L, Lee E-Y, Lin Y-P, Lin I-H, et al. Jing Si herbal drink as a prospective adjunctive therapy for COVID-19 treatment: molecular evidence and mechanisms. Pharmacol Res Mod Chin Med. 2022;2: 100024.

    Article  Google Scholar 

  40. Hsieh P-C, Chao Y-C, Tsai K-W, Li C-H, Tzeng I-S, Wu Y-K, et al. Efficacy and safety of complementary therapy with Jing Si Herbal Tea in patients with mild-to-moderate COVID-19: a prospective cohort study. Front Nutr. 2022;9: 832321.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Ping Y-H, Yeh H, Chu L-W, Lin Z-H, Hsu Y-C, Lin L-C, et al. The traditional Chinese medicine formula Jing Guan Fang for preventing SARS-CoV-2 infection: from clinical observation to basic research. Front Pharmacol. 2022;13: 744439.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Li J, Zhang K, Bao J, Yang J, Wu C. Potential mechanism of action of Jing Fang Bai Du San in the treatment of COVID-19 using docking and network pharmacology. Int J Med Sci. 2022;19:213–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Ma G, Chai X, Hou G, Zhao F, Meng Q. Phytochemistry, bioactivities and future prospects of mulberry leaves: a review. Food Chem. 2022;372: 131335.

    Article  CAS  PubMed  Google Scholar 

  44. Ma F, Shen W, Zhang X, Li M, Wang Y, Zou Y, et al. Anti-HSV activity of Kuwanon X from mulberry leaves with genes expression inhibitory and HSV-1 induced NF-κB deactivated properties. Biol Pharm Bull. 2016;39(10):1667–74.

    Article  CAS  PubMed  Google Scholar 

  45. Kim H, Chung MS. Antiviral activities of mulberry (Morus alba) juice and seed against influenza viruses. Evid Based Complement Alternat Med. 2018;2018:2606583.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Shakya A, Chikhale RV, Bhat HR, Alasmary FA, Almutairi TM, Ghosh SK, et al. Pharmacoinformatics-based identification of transmembrane protease serine-2 inhibitors from Morus Alba as SARS-CoV-2 cell entry inhibitors. Mol Divers. 2022;26(1):265–78.

    Article  CAS  PubMed  Google Scholar 

  47. Lin Z, Gan T, Huang Y, Bao L, Liu S, Cui X, et al. Anti-Inflammatory activity of Mulberry leaf flavonoids in vitro and in vivo. Int J Mol Sci. 2022;23(14):7694.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Yang M, Wang CC, Wang WL, Xu JP, Wang J, Zhang CH, Li MH. Saposhnikovia divaricata-an ethnopharmacological, phytochemical and pharmacological review. Chin J Integr Med. 2020;26(11):873–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Yang JL, Dhodary B, Quy Ha TK, Kim J, Kim E, Oh WK. Three new coumarins from Saposhnikovia divaricata and their porcine epidemic diarrhea virus (PEDV) inhibitory activity. Tetrahedron. 2015;71(28):4651–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Chun JM, Kim HS, Lee AY, Kim SH, Kim HK. Anti-Inflammatory and antiosteoarthritis effects of Saposhnikovia divaricata ethanol extract: in vitro and in vivo studies. Evid Based Complement Alternat Med. 2016;2016:1984238.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Chen Q, Lan HY, Peng W, Rahman K, Liu QC, Luan X, Zhang H. Isatis indigotica: a review of phytochemistry, pharmacological activities and clinical applications. J Pharm Pharmacol. 2021;73(9):1137–50.

    Article  PubMed  Google Scholar 

  52. Lin CW, Tsai FJ, Tsai CH, Lai CC, Wan L, Ho TY, et al. Anti-SARS coronavirus 3C-like protease effects of Isatis indigotica root and plant-derived phenolic compounds. Antiviral Res. 2005;68(1):36–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Yang L, Wang H, Yan H, Wang K, Wu S, Li Y. (-)-Lariciresinol isolated from the roots of Isatis indigotica Fortune ex Lindl. inhibits Hepatitis B virus by regulating viral transcription. Molecules. 2022;27(10):3223.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Lotts T, Kabrodt K, Hummel J, Binder D, Schellenberg I, Staender S, et al. Isatis tinctoria L.-derived petroleum ether extract mediates antiinflammatory affects via inhibition of interleukin-6, interleukin-33 and mast cell degranulation. Acta Derm Venereol. 2020;100(10):adv00131.

    Article  CAS  PubMed  Google Scholar 

  55. He XF, Geng CA, Huang XY, Ma YB, Zhang XM, Chen JJ. Chemical constituents from Mentha haplocalyx Briq. (Mentha canadensis L.) and their α-glucosidase inhibitory activities. Nat Prod Bioprospect. 2019;9(3):223–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Kakimoto M, Nomura T, Nazmul T, Kitagawa H, Kanno K, Ogawa-Ochiai K, et al. In vitro suppression of SARS-CoV-2 infection by existing kampo formulas and crude constituent drugs used for treatment of common cold respiratory symptoms. Front Pharmacol. 2022;13: 804103.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Kim SY, Han SD, Kim M, Mony TJ, Lee ES, Kim KM, et al. Mentha arvensis essential oil exerts anti-inflammatory in LPS-stimulated inflammatory responses via inhibition of ERK/NF-κB signaling pathway and anti-atopic dermatitis-like effects in 2,4-dinitrochlorobezene-induced BALB/c mice. Antioxidants (Basel). 2021;10(12):1941.

    Article  CAS  PubMed  Google Scholar 

  58. Zhao X, Zhou M. Review on chemical constituents of Schizonepeta tenuifolia Briq. and their pharmacological effects. Molecules. 2022;27(16):5249.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Ng YC, Kim YW, Lee JS, Lee SJ, Jung SM. Antiviral activity of Schizonepeta tenuifolia Briquet against noroviruses via induction of antiviral interferons. J Microbiol. 2018;56(9):683–9.

    Article  CAS  PubMed  Google Scholar 

  60. Chen SG, Cheng ML, Chen KH, Horng JT, Liu CC, Wang SM, et al. Antiviral activities of Schizonepeta tenuifolia Briq. against enterovirus 71 in vitro and in vivo. Sci Rep. 2017;7(1):935.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Kang H, Han SW, Hong JW, Sohn NW. Suppression of tumor necrosis factor-alpha by Schizonepeta tenuifolia water extract via inhibition of IkappaBalpha degradation and Jun N-terminal kinase/stress-activated protein kinase activation. J Pharm Pharmacol. 2010;62(8):1069–76.

    Article  CAS  PubMed  Google Scholar 

  62. Zhao Q, Chen X-Y, Martin C. Scutellaria baicalensis, the golden herb from the garden of Chinese medicinal plants. Sci Bull. 2016;61:1391–8.

    Article  CAS  Google Scholar 

  63. Liu H, Ye F, Sun Q, Liang H, Li C, Li S, et al. Scutellaria baicalensis extract and baicalein inhibit replication of SARS-CoV-2 and its 3C-like protease in vitro. J Enzyme Inhib Med Chem. 2021;36:497–503.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Wang Z, Yang L. Chinese herbal medicine: fighting SARS-CoV-2 infection on all fronts. J Ethnopharmacol. 2021;270: 113869.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Zhi H-J, Zhu H-Y, Zhang Y-Y, Lu Y, Li H, Chen D-F. In vivo effect of quantified flavonoids-enriched extract of Scutellaria baicalensis root on acute lung injury induced by influenza A virus. Phytomedicine. 2019;57:105–16.

    Article  CAS  PubMed  Google Scholar 

  66. Yoon S-B, Lee Y-J, Park SK, Kim H-C, Bae H, Kim HM, et al. Anti-inflammatory effects of Scutellaria baicalensis water extract on LPS-activated RAW 264.7 macrophages. J Ethnopharmacol. 2009;125:286–90.

    Article  PubMed  Google Scholar 

  67. Shingnaisui K, Dey T, Manna P, Kalita J. Therapeutic potentials of Houttuynia cordata Thunb. against inflammation and oxidative stress: a review. J Ethnopharmacol. 2018;220:35–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Chen X, Wang Z, Yang Z, Wang J, Xu Y, Tan R, et al. Houttuynia cordata blocks HSV infection through inhibition of NF-κB activation. Antiviral Res. 2011;92:341–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Wu Z, Deng X, Hu Q, Xiao X, Jiang J, Ma X, et al. Houttuynia cordata thunb: an ethnopharmacological review. Front Pharmacol. 2021;12: 714694.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Li W, Zhou P, Zhang Y, He L. Houttuynia cordata, a novel and selective COX-2 inhibitor with anti-inflammatory activity. J Ethnopharmacol. 2011;133:922–7.

    Article  PubMed  Google Scholar 

  71. Wu L-S, Si J-P, Yuan X-Q, Shi X-R. Quantitive variation of flavonoids in Houttuynia cordata from different geographic grigins in China. Chin J Nat Med. 2009;7:40–6.

    Article  CAS  Google Scholar 

  72. Huang R, Zhong T, Wu H. Quercetin protects against lipopolysaccharide-induced acute lung injury in rats through suppression of inflammation and oxidative stress. Arch Med Sci AMS. 2015;11:427–32.

    Article  PubMed  Google Scholar 

  73. El-Saber Batiha G, Magdy Beshbishy A, El-Mleeh A, Abdel-Daim M, Prasad Devkota H. Traditional uses, bioactive chemical constituents, and pharmacological and toxicological activities of Glycyrrhiza glabra L. (Fabaceae). Biomolecules. 2020;10:352.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Sharifi-Rad J, Quispe C, Herrera-Bravo J, Belén LH, Kaur R, Kregiel D, et al. Glycyrrhiza genus: enlightening phytochemical components for pharmacological and health-promoting abilities. Oxid Med Cell Longev. 2021;2021:1–20.

    Article  Google Scholar 

  75. Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr H. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet Lond Engl. 2003;361:2045–6.

    Article  CAS  Google Scholar 

  76. Passali D, Ciprandi G, Damiani V, De Marco AM, Cianfrone F, Passali FM. Glycyrrhizin for topical use and prophylaxis of COVID-19: an interesting pharmacological perspective. J Biol Regul Homeost Agents. 2021;35:15–9.

    CAS  PubMed  Google Scholar 

  77. Honda H, Nagai Y, Matsunaga T, Saitoh S, Akashi-Takamura S, Hayashi H, et al. Glycyrrhizin and isoliquiritigenin suppress the LPS sensor Toll-like receptor 4/MD-2 complex signaling in a different manner. J Leukoc Biol. 2012;91:967–76.

    Article  CAS  PubMed  Google Scholar 

  78. Lin Y-R, Chen H-H, Ko C-H, Chan M-H. Effects of honokiol and magnolol on acute and inflammatory pain models in mice. Life Sci. 2007;81:1071–8.

    Article  CAS  PubMed  Google Scholar 

  79. Kim H, Lim CY, Chung MS. Magnolia officinalis and its Honokiol and Magnolol constituents inhibit human norovirus surrogates. Foodborne Pathog Dis. 2021;18:24–30.

    Article  CAS  PubMed  Google Scholar 

  80. Tanikawa T, Hayashi T, Suzuki R, Kitamura M, Inoue Y. Inhibitory effect of honokiol on furin-like activity and SARS-CoV-2 infection. J Tradit Complement Med. 2022;1(2):69–72.

    Article  Google Scholar 

  81. Zhang F-H, Ren H-Y, Shen J-X, Zhang X-Y, Ye H-M, Shen D-Y. Magnolol suppresses the proliferation and invasion of cholangiocarcinoma cells via inhibiting the NF-κB signaling pathway. Biomed Pharmacother. 2017;94:474–80.

    Article  CAS  PubMed  Google Scholar 

  82. Wu X, Yu C, Cai W, Hua J, Li S, Wang W. Protective effect of a polyphenolic rich extract from Magnolia officinalis bark on influenza virus-induced pneumonia in mice. J Ethnopharmacol. 2011;134:191–4.

    Article  CAS  PubMed  Google Scholar 

  83. Kim SR, Seo HS, Choi H-S, Cho S-G, Kim YK, Hong EH, et al. Trichosanthes kirilowii ethanol extract and cucurbitacin D inhibit cell growth and induce apoptosis through inhibition of STAT3 activity in breast cancer cells. Evid Based Complement Alternat Med. 2013;2013: e975350.

    Article  Google Scholar 

  84. Ku JM, Kim SR, Hong SH, Choi H-S, Seo HS, Shin YC, et al. Cucurbitacin D induces cell cycle arrest and apoptosis by inhibiting STAT3 and NF-κB signaling in doxorubicin-resistant human breast carcinoma (MCF7/ADR) cells. Mol Cell Biochem. 2015;409:33–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Ha MT, Phan TN, Kim JA, Oh WK, Lee JH, Woo MH, et al. Trichosanhemiketal A and B: Two 13,14-seco-13,14-epoxyporiferastanes from the root of Trichosanthes kirilowii Maxim. Bioorganic Chem. 2019;83:105–10.

    Article  CAS  Google Scholar 

  86. Zheng YT, Ben KL, Jin SW. Anti-HIV-1 activity of trichobitacin, a novel ribosome-inactivating protein. Acta Pharmacol Sin. 2000;21:179–82.

    CAS  PubMed  Google Scholar 

  87. Wang X, Huang H, Ma X, Wang L, Liu C, Hou B, et al. Anti-inflammatory effects and mechanism of the total flavonoids from Artemisia scoparia Waldst. et kit. in vitro and in vivo. Biomed Pharmacother. 2018;104:390–403.

    Article  CAS  PubMed  Google Scholar 

  88. Ahn J-H, Park Y-L, Song A-Y, Kim W-G, Je C-Y, Jung D-H, et al. Water extract of Artemisia scoparia Waldst. & Kitam suppresses LPS-induced cytokine production and NLRP3 inflammasome activation in macrophages and alleviates carrageenan-induced acute inflammation in mice. J Ethnopharmacol. 2021;268:113606.

    Article  CAS  PubMed  Google Scholar 

  89. Ding J, Wang L, He C, Zhao J, Si L, Huang H. Artemisia scoparia: Traditional uses, active constituents and pharmacological effects. J Ethnopharmacol. 2021;273: 113960.

    Article  CAS  PubMed  Google Scholar 

  90. Dou Y, Tong B, Wei Z, Li Y, Xia Y, Dai Y. Scopoletin suppresses IL-6 production from fibroblast-like synoviocytes of adjuvant arthritis rats induced by IL-1β stimulation. Int Immunopharmacol. 2013;17:1037–43.

    Article  CAS  PubMed  Google Scholar 

  91. Yan H, Wang H, Ma L, Ma X, Yin J, Wu S, et al. Cirsimaritin inhibits influenza A virus replication by downregulating the NF-κB signal transduction pathway. Virol J. 2018;15:88.

    Article  PubMed  PubMed Central  Google Scholar 

  92. Geng CA, Chen JJ. The progress of Anti-HBV constituents from medicinal plants in China. Nat Prod Bioprospect. 2018;8(4):227–44.

    Article  PubMed  PubMed Central  Google Scholar 

  93. Zhan Y, Ta W, Tang W, Hua R, Wang J, Wang C, et al. Potential antiviral activity of isorhamnetin against SARS-CoV -2 spike pseudotyped virus in vitro. Drug Dev Res. 2021;82:1124–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Chao C-L, Huang H-W, Su M-H, Lin H-C, Wu W-M. The lanostane triterpenoids in Poria cocos play beneficial roles in immunoregulatory activity. Life. 2021;11:111.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Giner E-M, Máñez S, Recio M-C, Giner R-M, Cerdá-Nicolás M, Ríos J-L. In vivo studies on the anti-inflammatory activity of pachymic and dehydrotumulosic acids. Planta Med. 2000;66:221–7.

    Article  CAS  PubMed  Google Scholar 

  96. Ríos JL. Chemical constituents and pharmacological properties of Poria cocos. Planta Med. 2011;77(7):681–91.

    Article  PubMed  Google Scholar 

  97. Tian H, Liu Z, Pu Y, Bao Y. Immunomodulatory effects exerted by Poria Cocos polysaccharides via TLR4/TRAF6/NF-κB signaling in vitro and in vivo. Biomed Pharmacother. 2019;112: 108709.

    Article  CAS  PubMed  Google Scholar 

  98. Okonogi S, Kheawfu K, Holzer W, Unger FM, Viernstein H, Mueller M. Anti-inflammatory effects of compounds from Polygonum odoratum. Nat Prod Commun. 2016;11:1651–4.

    PubMed  Google Scholar 

  99. Pang X, Zhao J-Y, Liu N, Chen M-H, Zheng W, Zhang J, et al. Anthraquinone analogues with inhibitory activities against influenza a virus from Polygonatum odoratum. J Asian Nat Prod Res. 2021;23:717–23.

    Article  CAS  PubMed  Google Scholar 

  100. Liu X, Zhang M, Guo K, Jia A, Shi Y, Gao G, et al. Cellulase-assisted extraction, characterization, and bioactivity of polysaccharides from Polygonatum odoratum. Int J Biol Macromol. 2015;75:258–65.

    Article  CAS  PubMed  Google Scholar 

  101. Tian W-T, Zhang X-W, Liu H-P, Wen Y-H, Li H-R, Gao J. Structural characterization of an acid polysaccharide from Pinellia ternata and its induction effect on apoptosis of Hep G2 cells. Int J Biol Macromol. 2020;153:451–60.

    Article  CAS  PubMed  Google Scholar 

  102. Du W, Su J, Ye D, Wang Y, Huang Q, Gong X. Pinellia ternata attenuates mucus secretion and airway inflammation after inhaled corticosteroid withdrawal in COPD rats. Am J Chin Med. 2016;44:1027–41.

    Article  CAS  PubMed  Google Scholar 

  103. Lee M-Y, Shin I-S, Jeon W-Y, Lim H-S, Kim J-H, Ha H. Pinellia ternata Breitenbach attenuates ovalbumin-induced allergic airway inflammation and mucus secretion in a murine model of asthma. Immunopharmacol Immunotoxicol. 2013;35:410–8.

    Article  PubMed  Google Scholar 

  104. Chan T. Aconitum alkaloid poisoning related to the culinary uses of aconite roots. Toxins. 2014;6:2605–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  105. Nyirimigabo E, Xu Y, Li Y, Wang Y, Agyemang K, Zhang Y. A review on phytochemistry, pharmacology and toxicology studies of Aconitum. J Pharm Pharmacol. 2014;67:1–19.

    Article  PubMed  Google Scholar 

  106. Jin H, Ma N, Li X, Kang M, Guo M, Song L. Application of GC/MS-based metabonomic profiling in studying the therapeutic effects of Aconitum carmichaeli with ampelopsis japonica extract on collagen-induced arthritis in rats. Molecules. 2019;24:1934.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  107. Yan P, Mao W, Jin L, Fang M, Liu X, Lang J, et al. Crude Radix Aconiti Lateralis Preparata (Fuzi) with Glycyrrhiza reduces inflammation and ventricular remodeling in mice through the TLR4/NF-κB Pathway. Mediators Inflamm. 2020;2020:5270508.

    Article  PubMed  PubMed Central  Google Scholar 

  108. Xu H-Y, Zhang Y-Q, Liu Z-M, Chen T, Lv C-Y, Tang S-H, et al. ETCM: an encyclopaedia of traditional Chinese medicine. Nucleic Acids Res. 2019;47:D976–82.

    Article  CAS  PubMed  Google Scholar 

  109. Chang R, Chung PH, Rosenwaks Z. Role of acupuncture in the treatment of female infertility. Fertil Steril. 2002;78:1149–53.

    Article  PubMed  Google Scholar 

  110. Nestler G. Traditional Chinese medicine. Med Clin North Am. 2002;86:63–73.

    Article  PubMed  Google Scholar 

  111. Zhou W, Cheng X, Zhang Y. Effect of Liuwei Dihuang decoction, a traditional Chinese medicinal prescription, on the neuroendocrine immunomodulation network. Pharmacol Ther. 2016;162:170–8.

    Article  CAS  PubMed  Google Scholar 

  112. Che C-T, Wang ZJ, Chow MSS, Lam CWK. Herb-herb combination for therapeutic enhancement and advancement: theory, practice and future perspectives. Molecules. 2013;18:5125–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  113. Liu H, Zhou W, Gao Y. Discussions on toxic traditional Chinese medicine and new perspectives. World J Tradit Chin Med. 2019;5:145–50.

    Article  Google Scholar 

  114. Zhang J, Zhu Y, Fan X, Zhang B. Efficacy-oriented compatibility for component-based Chinese medicine. Acta Pharmacol Sin. 2015;36:654–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  115. Wang S, Hu Y, Tan W, Wu X, Chen R, Cao J, et al. Compatibility art of traditional Chinese medicine: from the perspective of herb pairs. J Ethnopharmacol. 2012;143:412–23.

    Article  PubMed  Google Scholar 

  116. Luan X, Zhang L-J, Li X-Q, Rahman K, Zhang H, Chen H-Z, et al. Compound-based Chinese medicine formula: from discovery to compatibility mechanism. J Ethnopharmacol. 2020;254: 112687.

    Article  CAS  PubMed  Google Scholar 

  117. Liu J, Feng W, Peng C. A song of ice and fire: cold and hot properties of traditional Chinese medicines. Front Pharmacol. 2021;11: 598744.

    Article  PubMed  PubMed Central  Google Scholar 

  118. Jin’ao D, Shulan S, Xinsheng F, Dawei Q, Yuping T, Erxin S, et al. Exploration of action patterns and mechanisms of traditional Chinese medicine incompatibility of Qi–Qing antagonism and mutual inhibition/restraint based on drug interaction. World Sci Technol. 2012;14:1547–52.

    Article  Google Scholar 

  119. Zhang Y, Qian D, Pan Y, Zhu Z, Huang J, Xi J, et al. Comparisons of the pharmacokinetic profile of four bioactive components after oral administration of Gan-Sui-Ban-Xia decoction plus-minus Gansui and Gancao drug combination in normal rats. Molecules. 2015;20:9295–308.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  120. Wu D, Xu T, Huang Z, Wang Y, Chen H, Chen Q, Chen L, et al. Systematic evaluation of toxicity of aconite based on bibliometric method. Evid Based Complement Alternat Med. 2021;2021:5514281.

    Article  PubMed  PubMed Central  Google Scholar 

  121. Sun F, Sheng Y, Fan S, Zhang Y, Zhuang P, Han J. β-2-Ar/PKA signal to investigate the toxic effect of aconite root and Trichosanthes kirilowii on inflammatory response and myocardial brosis in pressure overload rats. Chin J Tradit Chin Medicine. 2019;44(19):4212–8.

    Google Scholar 

  122. Colombo PC, Ganda A, Lin J, Onat D, Harxhi A, Iyasere JE, et al. Inflammatory activation: cardiac, renal, and cardio-renal interactions in patients with the cardiorenal syndrome. Heart Fail Rev. 2012;17(2):177–90.

    Article  CAS  PubMed  Google Scholar 

  123. Zhang W, Huai Y, Miao Z, Qian A, Wang Y. Systems Pharmacology for investigation of the mechanisms of action of traditional Chinese medicine in drug discovery. Front Pharmacol. 2019;10:743.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  124. Zhou G, Tang L, Zhou X, Wang T, Kou Z, Wang Z. A review on phytochemistry and pharmacological activities of the processed lateral root of Aconitum carmichaelii Debeaux. J Ethnopharmacol. 2015;160:173–93.

    Article  CAS  PubMed  Google Scholar 

  125. Liu X, Xie X, Luo M, Zhao Y, Li M, Peng F, et al. The synergistic compatibility mechanisms of fuzi against chronic heart failure in animals: a systematic review and meta-analysis. Front Pharmacol. 2022;13: 954253.

    Article  PubMed  PubMed Central  Google Scholar 

  126. Sun F, Huang Y, Li L, Wang Y, Zhuang P, Zhang Y. PKA/β2-AR-Gs/Gi signaling pathway is associated with anti-inflammatory and pro-apoptotic effects of Fuzi and Banxia combination on rats subjected to pressure overload. J Ethnopharmacol. 2019;235:375–84.

    Article  CAS  PubMed  Google Scholar 

  127. Sun F, Huang Y, Li L, Yang C, Zhuang P, Zhang Y. Fuzi and Banxia combination, eighteen antagonisms in Chinese medicine, aggravates adriamycin-induced cardiomyopathy associated with PKA/β2AR-Gs signaling. Evid-Based Complement Altern Med ECAM. 2018;2018:2875873.

    Article  Google Scholar 

  128. Liu J, Zhong G, Wang X, Ou L, Chen S. Chinese patent medicines containing eighteen incompatible herbs or nineteen mutual antagonistic herbs in Pharmacopoeia of People’s Republic of China (volume I, 2010). Chinese J Exp Traditional Med Formulae. 2011;17:213–7.

    CAS  Google Scholar 

  129. Cheng J, Jin H. Treatment of knee osteoarthritis with fumigation and washing of traditional Chinese medicine and sodium hyaluronate injection. J Sichuan Tradit Chin Medicine. 2008;26:97–8.

    Google Scholar 

  130. Li H. Treatment of 87 cases of knee joint osteoarthritis with integrated traditional Chinese and Western medicine. J Emerg Tradit Chin Medicine. 2004;13:250–1.

    Google Scholar 

  131. Jin H, Ma N, Li X, Kang M, Guo M, Song L. Application of GC/MS-based metabonomic profiling in studying the therapeutic effects of Aconitum carmichaeli with Ampelopsis japonica extract on collagen-induced arthritis in rats. Molecules. 2019;24(10):1934.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  132. Chen X, Cao Y, Zhang H, Zhu Z, Liu M, Liu H, et al. Comparative normal/failing rat myocardium cell membrane chromatographic analysis system for screening specific components that counteract doxorubicin-induced heart failure from Acontium carmichaeli. Anal Chem. 2014;86:4748–57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  133. Gao X, Zhang X, Hu J, Xu X, Zuo Y, Wang Y, et al. Aconitine induces apoptosis in H9c2 cardiac cells via mitochondria-mediated pathway. Mol Med Rep. 2018;17:284–92.

    CAS  PubMed  Google Scholar 

  134. Zhou YP. A review and thinking on the study of the radix Aconiti Lateralis Preparata-induced arrhythmia and antiarrhythmia effects. Pharmacol Clin Chin Mater Medica. 2015;31:153–8.

    CAS  Google Scholar 

  135. Yan S, Lu Y, Zhang G, Li X, Wang Z, Yao C, et al. Effect of heat-clearing and detoxifying Chinese medicines combined with conventional therapy on mild hand, foot, and mouth disease with fever: an individual patient data meta-analysis. Medicine (Baltimore). 2020;99: e20473.

    Article  PubMed  Google Scholar 

  136. Zhong LLD, Lam WC, Yang W, Chan KW, Sze SCW, Miao J, et al. Potential targets for treatment of coronavirus disease 2019 (COVID-19): a review of Qing-Fei-Pai-Du-Tang and its major herbs. Am J Chin Med. 2020;48:1051–71.

    Article  CAS  PubMed  Google Scholar 

Download references


We thank Iona J. MacDonald from China Medical University (Taichung, Taiwan) for her editing.


Not applicable.

Author information

Authors and Affiliations



GJH collected and analyzed literature and constructed all tables. YCS and JGL coordinated and jointly wrote and revised the paper. All authors read and approved the manuscript.

Corresponding author

Correspondence to Guan-Jhong Huang.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The National Institute of Traditional Chinese Medicine has obtained domestic and foreign “NRICM101” and “NRICM102” trademarks and patent applications.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lin, JG., Huang, GJ. & Su, YC. Efficacy analysis and research progress of complementary and alternative medicines in the adjuvant treatment of COVID-19. J Biomed Sci 30, 30 (2023).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: